The Qsymia REMS program is intended to help prevent:

Rationale

The Qsymia REMS program is intended to help prevent embryo-fetal exposure.

The Qsymia Risk Evaluation and Mitigation Strategy (REMS) program is specifically designed to mitigate risks associated with the use of Qsymia during pregnancy, particularly the risk of embryo-fetal exposure due to its teratogenic effects. This program ensures that both healthcare providers and patients are aware of the potential risks and necessary precautions.

A (Embryo-fetal exposure) CORRECT

This choice correctly identifies the primary focus of the Qsymia REMS program. Qsymia, which contains the active ingredients phentermine and topiramate, has been shown to pose risks to the developing fetus, including potential birth defects. The REMS program aims to prevent such exposure by ensuring proper prescribing and usage guidelines are followed.

B (Respiratory depression) YOUR ANSWER

While respiratory depression can be a concern with various medications, it is not the primary focus of the Qsymia REMS program. Qsymia is not specifically indicated for conditions that involve respiratory issues, and the REMS does not target this risk as part of its core objectives.

C (Fatal hemorrhage) YOUR ANSWER

Fatal hemorrhage is not associated with Qsymia use and is therefore not addressed by the REMS program. The medication primarily targets weight management, and while it has side effects, hemorrhage is not a recognized risk directly linked to its use.

D (Vision loss) YOUR ANSWER

Although vision-related side effects can occur with Qsymia, particularly with long-term use, the REMS program is not designed specifically to address vision loss. The emphasis is placed on preventing embryo-fetal exposure, which is a more critical concern given the implications for pregnant patients.

Conclusion

The Qsymia REMS program is primarily aimed at preventing embryo-fetal exposure due to the risks associated with its use during pregnancy. This critical focus distinguishes it from concerns such as respiratory depression, fatal hemorrhage, and vision loss, which are not central to the program's objectives. By managing these risks effectively, the REMS program ensures the safe use of Qsymia among patients who may become pregnant.

The Qsymia REMS program is intended to help prevent:

The Qsymia REMS program is intended to help prevent embryo-fetal exposure.

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test